Only 7% of CF providers indicated that they would potentially delay referral for patients currently taking a CFTR-modulator (Fig. 2a); however, 33% would delay referral for patients anticipated to soon qualify for a highly effective, CFTR-modulator therapy (Fig. 2b). The gene discussed is CFTR; the disease is cystic fibrosis.